What are the diagnostic criteria for Hemophagocytic Lymphohistiocytosis (HLH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH)

HLH is diagnosed when either a molecular diagnosis consistent with HLH is established OR when 5 out of 8 specific clinical and laboratory criteria are met according to the HLH-2004 guidelines. 1

The Two Pathways to Diagnosis

Pathway 1: Molecular Diagnosis

  • Genetic testing demonstrating mutations in HLH-associated genes (PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST, SH2D1A, BIRC4) establishes the diagnosis without requiring clinical criteria 1, 2

Pathway 2: Clinical Criteria (5 of 8 Required)

The 8 diagnostic criteria are: 1, 2

  1. Fever (persistent, unexplained)

  2. Splenomegaly (clinical or radiographic)

  3. Cytopenias affecting ≥2 of 3 lineages:

    • Hemoglobin < 90 g/L (< 100 g/L in infants < 4 weeks)
    • Platelets < 100 × 10⁹/L
    • Neutrophils < 1.0 × 10⁹/L
  4. Hypertriglyceridemia and/or hypofibrinogenemia:

    • Fasting triglycerides ≥ 3.0 mmol/L (≥ 265 mg/dL)
    • Fibrinogen ≤ 1.5 g/L
  5. Hemophagocytosis in bone marrow, spleen, or lymph nodes (with no evidence of malignancy)

  6. Low or absent NK cell activity (according to local laboratory reference)

  7. Ferritin ≥ 500 mg/L

  8. Soluble CD25 (sCD25/soluble IL-2 receptor) ≥ 2400 U/mL

Critical Diagnostic Considerations

When to Suspect HLH Despite Not Meeting Full Criteria

Treatment may be initiated even when fewer than 5 criteria are met if clinical suspicion is high. 1 This is particularly important because HLH is rapidly fatal without treatment, and waiting for all criteria can delay life-saving therapy.

Hyperferritinemia as a Key Diagnostic Clue

  • Ferritin > 10,000 mg/L is 90% sensitive and 96% specific for HLH and should immediately trigger comprehensive HLH evaluation 3
  • Adult HLH typically presents with ferritin 7,000-10,000 mg/L, occasionally exceeding 100,000 mg/L 1, 2
  • While the diagnostic threshold is only 500 mg/L, such modest elevations are nonspecific; values > 10,000 mg/L are far more diagnostically useful 1, 3

Soluble IL-2 Receptor (sCD25) Performance

  • sCD25 has superior diagnostic accuracy compared to ferritin (AUC 0.90 vs 0.78) and is an excellent low-cost test for adult HLH 1, 2
  • This marker may be particularly valuable when ferritin is equivocal or when rapid diagnosis is needed

The Challenge of Hemophagocytosis

  • Hemophagocytosis may be absent initially and should not delay diagnosis or treatment 1, 2
  • If initial bone marrow is negative, obtain material from other organs (liver, spleen, lymph nodes) or perform serial marrow aspirates over time 1, 2
  • The absence of hemophagocytosis does not exclude HLH if other criteria are met

Alternative Diagnostic Tool: The HScore

For adults with suspected secondary HLH, the HScore provides a validated alternative to HLH-2004 criteria. 1, 2 This scoring system was developed specifically for adults and includes:

  • Known underlying immunosuppression (HIV or long-term immunosuppressive therapy): 0 or 18 points
  • Temperature: 0 (< 38.4°C), 33 (38.4-39.4°C), or 49 (> 39.4°C) points
  • Organomegaly: 0 (none), 23 (hepatomegaly OR splenomegaly), or 38 (both) points
  • Number of cytopenias: 0 (1 lineage), 24 (2 lineages), or 34 (3 lineages) points
  • Ferritin: 0 (< 2000 mg/L), 35 (2000-6000 mg/L), or 50 (> 6000 mg/L) points
  • Triglycerides: 0 (< 1.5 mmol/L), 44 (1.5-4 mmol/L), or 64 (> 4 mmol/L) points
  • Fibrinogen: 0 (> 2.5 g/L) or 30 (≤ 2.5 g/L) points
  • AST: 0 (< 30 U/L) or 19 (≥ 30 U/L) points
  • Hemophagocytosis on bone marrow: 0 (no) or 35 (yes) points 1, 2

Supportive Findings That Strengthen the Diagnosis

Additional clinical and laboratory abnormalities that support HLH include: 1, 2

  • CSF pleocytosis (mononuclear cells) and/or elevated CSF protein
  • Liver biopsy showing chronic persistent hepatitis pattern
  • Cerebromeningeal symptoms
  • Lymph node enlargement
  • Jaundice, edema, skin rash
  • Hepatic enzyme abnormalities
  • Hypoproteinemia, hyponatremia
  • Elevated VLDL with low HDL

Critical Pitfalls to Avoid

Validation Limitations

  • The HLH-2004 criteria were developed for children and remain based on expert opinion for adults, not formal validation 1, 2, 4
  • Despite this limitation, they remain the standard diagnostic approach in clinical practice

Diagnostic Mimickers

  • HLH can be extremely difficult to distinguish from sepsis/septic shock, systemic inflammatory response syndrome, or severe viral infections in critically ill patients 5, 4
  • Many diagnostic features are nonspecific, requiring integration of multiple clinical findings rather than relying on any single criterion 1, 4

Laboratory Turnaround Time

  • NK cell functional assays and sCD25 levels often require send-out to specialized laboratories, potentially delaying diagnosis by days 3, 4
  • Ferritin is available same-day at most institutions and should be used as an immediate screening tool 3

The Danger of Delayed Diagnosis

  • Do not wait for all diagnostic criteria or specialized test results before initiating treatment when clinical suspicion is high 1, 2
  • HLH is rapidly fatal without treatment, and mortality increases significantly with diagnostic delays 5, 4
  • Two patients in one case series died within days of HLH diagnosis from DIC and multiorgan failure 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis.

Clinical lymphoma, myeloma & leukemia, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.